Prof. Dr. RAINER SPANAGEL

1) General information

Date of birth: 24 June, 1961

Gender: Male

Address: Heidelberg University

Medical Faculty Mannheim
Department of Psychiatry and

Psychotherapy

Central Institute for Mental Health

J5

68159 Mannheim, Germany

Phone: +49-(0)621-17036251

E-mail: rainer.spanagel@zi-mannheim.de

Current position: Scientific Director of the Institute of Psychopharmacology (W3)

Children: Two (*1991, *2006) Parental leave, if applicable: None



1983 - 1989 Universities of Tübingen and Munich (Biology)

3) Advanced academic qualifications

Habilitation, Pharmacology & Toxicology, University of Munich, Germany,

Prof. Wolfgang Forth

1991 Ph.D., Neuropharmacology, Max Planck Institute of Neuropharmacology,

Martinsried, Germany. Supervisor: Prof. Albert Herz

1989 Diploma Neuropharmacology, Max Planck Institute of Neuropharmacology

Martinsried, Germany

4) Postgraduate professional career

Since 2011 Scientific Director of the Institute of Psychopharmacology at the CIMH,

Mannheim, Germany

Since 2006 W3 Professor and member of the Board of Directors at the Central Institute of

Mental Health (CIMH), Mannheim, Germany

Since 2000 Department Head of Psychopharmacology at the CIMH, Mannheim, Germany 1999 - 2000 Professor for Psychopharmacology at the University of Heidelberg, Germany

1995 - 1999 Head of the Research Group "Drug Addiction" at the Max Planck Institute of

Psychiatry, Munich, Germany

1991 - 1995 Scientific assistant at the Max Planck Institute of Psychiatry, Munich (Prof.

Florian Holsboer), Germany

5) Other

Awards and honours:

2019 H. David Archibald Lectureship Award from CAMH, Toronto

2018 IBANGS Distinguished Investigator Award



| 2017 European Alcohol Research Award, ESBRA | | | | | | | |
|---|-------|--|--|--|--|--|--|
| 2015 NEATOR Award from American College of Neuropsychopharmacology | | | | | | | |
| 2011 AGNP Award for Excellence in Psychopharmacology | | | | | | | |
| 2010 Reinhart-Koselleck-Award from the DFG | | | | | | | |
| 2008 James B. Isaacson Award | | | | | | | |
| 2005 Albrecht-Ludwig-Berblinger Award | | | | | | | |
| 2003 Sir Hans Krebs Award | | | | | | | |
| 1998 Wilhelm Feuerlein Award for Alcohol Research | | | | | | | |
| | | | | | | | |
| Panels and coordinating functions | | | | | | | |
| Since 2005 Executive member of the Society of Studies on Addiction (SSA) | | | | | | | |
| Since 2008 Executive member of the International Society of Biomedical Research or | 1 | | | | | | |
| Alcoholism (ISBRA), and the ECNP (SAB) | | | | | | | |
| Since 2005 MEMBERSHIPS OF SCIENTIFIC SOCIETIES: Member of F1000 | | | | | | | |
| (Pharmacology Section) Member of ISBRA, RSA, ESBRA, EBPS, ISN, Do | GPT, | | | | | | |
| AGNP, NWG | | | | | | | |
| 2014 - 2018 Scientific Advisory Board of the European Monitoring Centre for Drugs an | d | | | | | | |
| Drug Addiction (EMCDDA) in Lisbon | | | | | | | |
| 2016 - 2018 President of the International Society of Biomedical Research on Alcoholi | sm | | | | | | |
| (ISBRA) | | | | | | | |
| 2016 President and Organizer of the World Congress on Alcohol Research in B | erlin | | | | | | |
| 2014 - 2018 Coordinator of the German Research Network on Systems Medicine in | | | | | | | |
| Alcohol Addiction (e:Med) | | | | | | | |
| 2008 - 2017 Member of Scientific Advisory Board of ECNP | | | | | | | |
| 2008 - 2014 Coordinator of the German Research Network on Genetics of Alcoholism | | | | | | | |
| (NGFN) | | | | | | | |
| 2020 - present Spokesperson of the e:Med Project Committee (www.sys- | | | | | | | |
| med.de/en/emed/players/project-committee) | | | | | | | |
| 2019 - 2022 Coordinator of the European Psi-Alc Consortium www.psialc.org | | | | | | | |
| 2019 - 2022 Coordinator of the German Research Network on Systems Medicine in Dr | ug | | | | | | |
| Addiction e:Med | | | | | | | |
| Founder of the 3R Center Rhein/Neckar that includes Heidelberg University | ity | | | | | | |
| and CIMH | | | | | | | |
| | | | | | | | |
| Editorial boards: | | | | | | | |
| 2003 - 2016 Member of the Editorial Board Alcoholism Clinical and Experimental Rese | arch | | | | | | |
| 2003 - 2009 Member of the Editorial Board of Addiction | | | | | | | |
| Since 2005 Editor-in-Chief of 'Addiction Biology' | | | | | | | |
| 2009 - 2019 Associate Editor of Frontiers in Behavioral Neuroscience | | | | | | | |
| Since 2010 Associate Editor of Substance Abuse and Rehabilitation | | | | | | | |
| Since 2011 Associate Editor of Frontiers in Genetics | | | | | | | |
| Since 2011 Member of the Editorial Board of Behavioural Brain Research | | | | | | | |
| 2040 2040 Falton in Objet the Eller Discourse allered | | | | | | | |
| 2012 - 2018 Editor-in-Chief 'In silico Pharmacology' | | | | | | | |
| 2012 - 2018 Editor-in-Chief 'In silico Pharmacology' 2014 - 2020 Member of the Editorial Board of Journal of Neurochemistry 2015 - 2020 Member of the Editorial Board of International Journal of | | | | | | | |

Neuropsychopharmacology

Since 2016 Member of the Editorial Board Genes

2016 - 2018 Member of the Editorial Board of Naunyn-Schmiedeberg's Archives of

Pharmacology

2019 - Specialty Chief Editor of Frontiers of Behavioural Neuroscience

6) Publications

A)

- Meinhardt MW, Pfarr S, Rohleder C, Vengeliene V, Barroso-Flores J, Hoffmann R, Meinhardt ML, Paul E, Hansson AC, Köhr G, Meier N, von Bohlen und Halbach O, Bell RL, Endepols H, Schönig K, Bartsch D, Naassila M, <u>Spanagel R*</u>, Sommer WH*. Psilocybin targets a common molecular mechanism for cognitive impairment and increased craving in alcoholism. **Science Advances**; 7(47):eabh2399, 2021.
- Noori HR, Mervin LH, Bokharaie V, Durmus Ö, Egenrieder L, Fritze S, Gruhlke B, Reinhardt G, Schabel HH, Staudenmaier S, Logothetis NK, Bender A, <u>Spanagel R</u> (2018) Systemic neurotransmitter responses to clinically approved and experimental neuropsychiatric drugs. **Nature Communication**; 9(1):4699, 2018.
- Hirth N, Meinhardt MW, Noori HR, Salgado H, Torres-Ramirez O, Uhrig S, Broccoli L, Vengeliene V, Rossmanith M, Perreau-Lenz S, Kohr G, Sommer WH, <u>Spanagel R*</u>, Hansson AC. Convergent evidence from alcohol-dependent humans and rats for a hyperdopaminergic state in protracted abstinence. **PNAS**; 113(11):3024-3029, 2016.
- Wiens F, Zitzmann A, Lachance MA, Yegles M, Pragst F, Wurst FM, von Holst D, Guan SL, Spanagel R. Chronic intake of fermented floral nectar by wild treeshrews. **PNAS**; 105(30):10426-10431, 2008.
- Engblom D, Bilbao A, Sanchis-Segura C, Dahan L, Perreau-Lenz S, Balland B, Parkitna JR, Lujan R, Halbout B, Mameli M, Parlato R, Sprengel R, Luscher C, Schutz G, <u>Spanagel R</u>. Glutamate receptors on dopamine neurons control the persistence of cocaine seeking. **Neuron**; 59(3):497-508, 2008.
- <u>Spanagel R</u>, Pendyala G, Abarca C, Zghoul T, Sanchis-Segura C, Magnone MC, Lascorz J, Depner M, Holzberg D, Soyka M, Schreiber S, Matsuda F, Lathrop M, Schumann G, Albrecht U. The clock gene Per2 influences the glutamatergic system and modulates alcohol consumption. **Nature Medicine**; 11(1):35-42, 2005.
- Sillaber I, Rammes G, Zimmermann S, Mahal B, Zieglgansberger W, Wurst W, Holsboer F, Spanagel R. Enhanced and delayed stress-induced alcohol drinking in mice lacking functional CRH1 receptors. **Science**; 296(5569):931-933, 2002.
- Abarca C, Albrecht U, <u>Spanagel R</u>. Cocaine sensitization and reward are under the influence of circadian genes and rhythm. **PNAS**; 99(13):9026-9030, 2002.
- Timpl P, <u>Spanagel R*</u>, Sillaber I, Kresse A, Reul JM, Stalla GK, Blanquet V, Steckler T, Holsboer F, Wurst W. Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1. **Nature Genetics**; 19(2):162-166, 1998.
- <u>Spanagel R</u>, Herz A, Shippenberg TS. Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway. **PNAS**; 89(6):2046-2050, 1992.

| Sı | рa | na | ae | I. | R. |
|----|----|----|----|----|----|
| | | | | | |

B) other publications: -

C) Patents:

Granted:

EU patent (2016) EU Patent Application No 14155868.4 - Mutated Receptor Polypeptide and Use Thereof